New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg SPINRAZA® (nusinersen) Final results from the landmark NURTURE study highlight the profound impact of early treatment with 12 mg SPINRAZA in clinically presymptomatic SMA with 92% of children achieving the ability to walk independently CAMBRIDGE, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) ...

American Rebel Holdings Inc American Rebel Light Beer Online Orders Soar as American Rebel Beer Ships to Over 40 States; Free Shipping Available Through June 30 NASHVILLE, TN, June 26, 2025 (GLOBE NEWSWIRE) -- American Rebel Holdings, Inc. (NASDAQ: AREB) ("American Rebel" or the "Company"), creator of American Rebel Beer (americanrebelbeer.com) and a designer, manufacturer, and marketer of branded safes, personal security and self-defense products and apparel, proudly reports explosive online sales grow ...

Recognition highlights EluPro™ Antibiotic-Eluting BioEnvelope’s impact on device protection for cardiac implantable electronic devices (CIEDs) and neurostimulators SILVER SPRING, Md., June 26, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, has been recognized with two prestigious honors—Innovation and Product Launches—in the 2025 Medical Device Network Excellence Awards. The awards celebrate Elutia’s advancements in drug el ...

YUPELRI approved by China's NMPA as the first once-daily nebulized LAMA for maintenance treatment of COPD Approval triggers $7.5 million milestone payment from Viatris, with eligibility to receive further sales milestones and tiered royalties on net sales in China Theravance Biopharma incurs no commercial costs in China; Viatris is responsible for the launch and commercializationDUBLIN, June 26, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today a ...

Core Insights - Biogen Inc. announced topline results from the Phase 1 study of salanersen, an antisense oligonucleotide for spinal muscular atrophy (SMA), showing potential for high efficacy and once yearly dosing [1][5] - The Phase 1 study demonstrated substantial slowing of neurodegeneration and clinically meaningful improvements in motor function in children previously treated with gene therapy [2][5] - Biogen is engaging with global health authorities to advance salanersen into registrational studies based on encouraging Phase 1 data [4][5] Study Details - The Phase 1 study included two parts: a randomized placebo-controlled segment in healthy adults and an open-label segment in pediatric SMA participants who had previously received ZOLGENSMA [2][4] - Interim results from the open-label segment (n=24) indicated that both 40 mg and 80 mg doses of salanersen were well-tolerated, with a mean reduction in neurofilament light chain (NfL) of 70% at 6 months [2][4] - Exploratory data showed that half of the participants (4 out of 8) achieved new WHO motor milestones after receiving salanersen [3][4] Safety Profile - The safety profile of salanersen was generally well-tolerated, with most adverse events being mild to moderate, including pyrexia and upper respiratory tract infections [4][5] - The study's findings suggest that salanersen could address critical unmet needs in SMA treatment, building on Biogen's extensive experience in the field [3][5] Industry Context - SMA is a rare genetic neuromuscular disease affecting approximately 1 in 10,000 live births, characterized by progressive muscle atrophy and weakness [7][8] - SPINRAZA, another treatment for SMA, has been approved in over 71 countries and has treated more than 14,000 individuals worldwide, establishing a foundation of care in SMA [9][10]

Markets rise and fall, booms come and go, and the world keeps ticking. Ultimately, I believe observing megatrends, as difficult as they can be to spot, let alone fully comprehend, can yield insights into the advance of human society, which in turn could pave the way for many useful investment insights. As society and technologies evolve, companies and other stakeholders will seize advantages. Figuring out which companies will take the best advantage of any given opportunities is not easy. I am especially in ...

Guggenheim Partners on Monday initiated coverage on Amylyx Pharmaceuticals, Inc. AMLX, noting the company is poised to open post-bariatric hypoglycemia’s (PBH) blockbuster potential.PBH is a common complication where blood sugar levels drop too low after meals in individuals who have undergone bariatric (tummy tuck) surgery.Analyst Seamus Fernandez initiated a Buy rating and a price forecast of $17, saying, “In our view, AMLX offers a compelling investment opportunity in first-in-class rare diseases medicin ...

Sono Luca Monti, raccolgo il timone dalla nostra bella e brava, io non sono bello, forse sono bravo. Giuditta Avellina e io sono ho incontrato per caso dei ragazzi meravigliosi che sono quelli che poi mi hanno invitato qui oggi perché all'università tante voci avete sentito della nostra università, io mi occupo di eventi culturali e in particolare vi parlerò oggi di questo tema, i grandi eventi che costruiscono o cambiano le città. Eh, e per farlo e non sono bravo come i ragazzi che avete sentito prima, ma ...

[Música] Boa tarde. Bem, obrigado pela introdução, Marta. Eu ia pegar aqui nesta parte de Guilherme Félix é ator e dizer que eu ah, na verdade muitos de vocês podiam ter esta, introdução, mas se calhar retirava aquela parte da matemática.Hum. Eu digo isto porquê. Porque na verdade todos nós representamos no nosso dia- a dia, todos nós temos vários papéis, várias personagens, não nos mostramos a 100% a toda a gente.Histo é muito fácil de pensar porque basta nós pensarmos como é que nos comportamos num grupo ...

3 weeks ago, 238 Venezuelan migrants were flown from Texas to a maximum security prison in El Salvador. That country's president offered to take them and the Trump administration used a law not invoked since World War II to send them, claiming they are all terrorists and violent gang members. The government has released very little information about the men.But through internal government documents, we've obtained a list of their identities and found that an overwhelming majority have no apparent criminal c ...